I have focused my clinical research in understanding the heterogeneity of cardiometabolic disease and what factors are associated with the greatest risk of developing type 2 diabetes and cardiovascular disease. I have developed a three-pronged research program that is unified under this theme. The first arm includes the creation of a South Asian longitudinal cohort to study multilevel risk factors in a very high risk ethnic group. The second arm uses existing data from prospective cohort studies to test biomarkers that predict diabetes and cardiovascular disease. The final arm tests behavioral interventions to prevent the onset of diabetes.
The first arm of my research program has been to establish a community-based prospective cohort of South Asian adults. South Asians have a high prevalence of diabetes and cardiovascular disease. In 2006, with a K23 grant from the NHLBI, we recruited 150 Asian Indians in a pilot cohort study called MASALA (Metabolic syndrome and Atherosclerosis in South Asians Living in America) which was modelled on the Multi-Ethnic Study of Atherosclerosis (MESA). We found that compared to the four ethnic groups in MESA, Indians had higher diabetes and atherosclerosis prevalence, despite having favorable lifestyle behaviors. This unique phenotype--with modest BMI levels but high levels of adiposity and diabetes--provided an ideal population to understand adiposity biomarkers and body composition. With these preliminary data, I received R01 funding in 2010 to expand and prospectively follow a South Asian cohort to 900 individuals at two clinical sites to better chart the natural history of atherosclerosis, also called MASALA (Mediators of Atherosclerosis in South Asians Living in America). We completed the baseline study visit for this large cohort in 2013 and received an R01 renewal to conduct our second clinical examination of the MASALA cohort in 2015. With philanthropic support, we expanded the cohort from 906 to 1,164 South Asian participants who are being followed prospectively for cardiovascular disease events. In 2021, we received another NHLBI R01 to conduct Exam 3 in our surviving MASALA cohort, focusing on cardiovascular function. Our team was also awarded an R01 from NIMHD in 2021 to expand our cohort by enrolling 1,164 Bangladeshi and Pakistani individuals to have greater diversity of South Asians and enough statistical power to determine whether and why there are differences in risk factors among the three largest South Asian American subgroups. This cohort has received national and global attention since it is one of a handful of cohorts studying this high risk population group and MASALA has deeper phenotyping than any other South Asian cohort allowing for opportunities to study many related outcomes.
The second arm of my research program focuses on understanding novel biomarkers that may be responsible for the metabolic sequelae associated with obesity. I have assayed novel biomarkers (adiponectin, F2-isoprostanes, and fluorescent oxidative products) from biospecimens in a longitudinal cohort, the Health, Aging and Body Composition Study. I performed a series of analyses finding that abdominal visceral adiposity when directly measured by CT scan is significantly associated with type 2 diabetes and adiponectin and PAI-1 explain this association. We have found strong associations, with these adipokines predicting risk of future diabetes, cardiovascular disease, and mortality. Over the past decade, I have been mentoring two investigators, Drs. Meghana Gadgil and Elena Flowers, in developing their research program on developing metabolomic and microRNA biomarkers that are associated with type 2 diabetes risk. These biomarkers improve our etiologic understanding of the links between obesity and diabetes and may soon be useful clinically in improving our risk stratification for diabetes.
The third arm of my research agenda includes testing behavioral interventions to prevent and/or delay the onset of type 2 diabetes in high risk individuals. We completed a translational randomized controlled trial testing the effectiveness of a lifestyle intervention provided by the Berkeley Public Health Department to decrease diabetes risk factors in low-income ethnic minority groups (ref #64, 75). We found that a phone-based lifestyle intervention was effective in promoting weight loss, lowering triglycerides and improving diet. I also led a randomized controlled trial of restorative yoga vs. stretching in overweight and less active adults with the metabolic syndrome (PRYSMS study). We randomized 180 individuals at two clinical centers and found that restorative yoga significantly improved fasting glucose levels compared to stretching. These behavioral interventions will offer clinicians and patients helpful alternatives in reducing their risk for diabetes.
The three arms of my research agenda complement each other and provide fertile ground to develop and test new hypotheses with the ultimate goal of better caring for patients at high risk of diabetes and cardiovascular disease.